Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 10/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15165605 | 1.00 | SLC29A1 (0.46) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL13239682 | 0.84 | SLC29A1 (0.48) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL15165604 | 0.84 | SLC29A1 (0.48) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL15165611 | 0.81 | DNPH1 (0.40) | SLC29A1HIF1A | |
| SCHEMBL15165601 | 0.76 | SLC29A1 (0.44) | SLC29A1SLC28A3 | |
| SCHEMBL13239677 | 0.76 | SLC29A1 (0.44) | SLC29A1SLC28A3 | |
| SCHEMBL15165609 | 0.75 | DNPH1 (0.44) | SLC29A1 | |
| SCHEMBL13239692 | 0.75 | DNPH1 (0.44) | SLC29A1 | |
| SCHEMBL14030794 | 0.73 | EHMT1 (0.43) | SLC29A1TP53SLC28A3 | |
| SCHEMBL2196289 | 0.72 | CYP1A2 (0.56) | SLC29A1TP53CYP3A4HIF1AABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | SLC29A1 19/4885TP53 4142/4885CYP3A4 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.